Alumis (ALMS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Voting matters and shareholder proposals
Election of three Class II director nominees to serve until the 2029 annual meeting: James B. Tananbaum, M.D., Lynn Tetrault, J.D., and Zhengbin (Bing) Yao, Ph.D. are recommended for election.
Ratification of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2026.
Board of directors and corporate governance
Board recommends the election of the three named director nominees for multi-year terms ending in 2029.
Audit committee and external auditor matters
Proposal to ratify PricewaterhouseCoopers LLP as the external auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Alumis
- Envudeucitinib advances in psoriasis and targeted lupus populations, with new CNS and pipeline programs progressing.ALMS
Wells Fargo 21st Annual Healthcare Conference - Envudeucitinib showed strong efficacy in IFNGS-high SLE patients, supporting Phase 3 focus.ALMSStudy result
- Envudeucitinib and A-005 deliver leading efficacy in immune diseases, targeting $180B+ markets.ALMSCorporate presentation
- Envudeucitinib set a new efficacy benchmark in psoriasis; Q2 net loss was $142.2M with $502.3M cash.ALMSQ2 2026
- Annual meeting to elect directors and ratify auditor, with strong governance and transparency.ALMSProxy filing
- Envudeucitinib delivers leading efficacy in psoriasis, with broad TYK2 franchise potential.ALMSCorporate presentation
- Envudeucitinib's Phase 3 success drives NDA plans as $569.5M cash supports operations into 2027.ALMSQ1 2026
- Envudeucitinib achieved rapid, sustained skin clearance and symptom relief with strong safety in Phase 3 trials.ALMSStudy update
- Envudeucitinib achieved top Phase 3 results in psoriasis, driving a high-value, multi-indication pipeline.ALMSCorporate presentation